Genetic Technologies Limited Provides End of Year Update on the Test Development Program
December 21 2018 - 5:30AM
Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”), a
diversified molecular diagnostics company embracing blockchain
technologies across genomic testing platforms, provides today an
update on its R&D program for the year.
Excellent R&D progress in 2018,
approaching commercialisation early in 2019
As announced to the market on 16th March 2018,
Genetic Technologies Limited has embarked on a collaborative
research program with academic research staff from the Centre for
Epidemiology and Biostatistics at The University of Melbourne. Led
by Professor John Hopper, the research is designed to broaden the
applicability of the BREVAGenplus® breast cancer risk assessment
test enabling its use in women with an extended family history of
disease and will also increase the range of risk factors
analysed.
We are pleased to report that the validation
studies for the improved risk test are now complete and the
internal procedures for commercialization and implementation are
now underway. We expect the new product to be available to the
medical community at the end of Q1 2019.
Internal procedures for implementing a new
colorectal cancer risk test are nearing completion and we expect
the new product to be available to the medical community within a
similar timescale at the end of Q1 2019. As part of this process a
focus-group comprising local physicians and colorectal cancer
experts has been scheduled to provide guidance on the practical
implementation of the test and best practice reporting requirements
for the patient test results.
As further announced to the market on 16 July
2018, the Company has initiated development of several new genetic
risk prediction tests, initially focusing on:
- Updated Breast Cancer Risk Test
- Implementation of Colorectal Cancer test
- Prostate Cancer
- Melanoma
- Type 2 Diabetes
- Cardiovascular Disease
Established cohorts of case-control data
necessary to validate these new tests have now been identified and
we are in the process of formally requesting access to the
necessary data with the intent of making the new products available
to the medical community within the first half of 2019.
FOR
FURTHER INFORMATION PLEASE CONTACT |
Dr Paul
Kasian |
Jason Wong
(USA) |
Director & Interim
CEO |
Blueprint Life Science
Group |
Genetic Technologies
Limited |
+1 (415) 375 3340, Ext.
4 |
+ 61 3 8412 7000 |
|
|
|
About Genetic Technologies
LimitedGenetic Technologies is a diversified molecular
diagnostics company embracing blockchain technologies across
genomic testing platforms. GTG offers cancer predictive testing and
assessment tools to help physicians proactively manage patient
health. The Company’s lead product, BREVAGenplus®, is a clinically
validated risk assessment test for non-hereditary breast cancer and
is first in its class. For more information, please visit
www.brevagenplus.com and www.phenogensciences.com.Genetic
Technologies is developing a pipeline of risk assessment products
including a novel colorectal cancer (CRC) test. For more
information, please visit www.gtgcorporate.com
Safe Harbor StatementAny
statements in this press release that relate to the Company's
expectations are forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act. The Private
Securities Litigation Reform Act of 1995 (PSLRA) implemented
several significant substantive changes affecting certain cases
brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024